Shimon Harary, MD
Endocrinology, Diabetes & Metabolism · Memphis, TNNPI 1801030192
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $674,583 of the $734,576 with a category attached, or 91.8%. Lilly USA, LLC accounts for 61.7% of it on its own, with 34 other manufacturers making up the rest. Among endocrinology, diabetes & metabolism clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,323 payments — averaging $555.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$453K
- Boehringer Ingelheim$136K
- Novo Nordisk$111K
- Xeris Pharmaceuticals, Inc.$18K
- Abbott$8K
- Medtronic$6K
- plus $2K from 29 others
What the payments were for
- Consulting fees$22,7383%
- Speaking & faculty fees$674,58392%
- Travel & lodging$26,5994%
- Food & beverage$10,6421%
- Education$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 780 | $452,935 |
| Boehringer Ingelheim | 212 | $135,869 |
| Novo Nordisk | 121 | $111,355 |
| Xeris Pharmaceuticals, Inc. | 41 | $18,343 |
| Abbott | 18 | $7,838 |
| Medtronic(2 entities) | 28 | $6,191 |
| Amgen(2 entities) | 38 | $510 |
| Sanofi-aventis U.S. LLC | 12 | $193 |
| AbbVie | 13 | $169 |
| Cequr Corporation | 2 | $165 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $131 |
| Merck | 9 | $122 |
| Corcept Therapeutics | 5 | $117 |
| Mannkind Corporation | 5 | $95 |
| Insulet Corporation | 3 | $58 |
| AstraZeneca(2 entities) | 3 | $47 |
| Sequel Med Tech, LLC | 2 | $44 |
| Recordati_rare_diseases_inc. | 2 | $38 |
| Pfizer | 2 | $33 |
| Radius Health, Inc. | 2 | $31 |
| Nevro Corp. | 2 | $30 |
| IBSA Pharma Inc. | 2 | $30 |
| Optos, Inc. | 1 | $23 |
| Antares Pharma, Inc. | 1 | $23 |
| Verity Pharmaceuticals Inc. | 1 | $23 |
| Novartis | 1 | $22 |
| Abiomed | 1 | $21 |
| EUSA Pharma (US) LLC | 1 | $20 |
| Azurity Pharmaceuticals, Inc. | 1 | $20 |
| Amarin Pharma, Inc. | 1 | $18 |
| GRT US Holding, Inc. | 1 | $16 |
| Shire North American Group Inc | 1 | $15 |
| Johnson & Johnson | 1 | $14 |
| Ultragenyx Pharmaceutical Inc. | 1 | $12 |
| Clarus Therapeutics Inc. | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$317,621
- MOUNJARO$161,907
- RYBELSUS$51,359
- Ozempic$49,015
- HUMULIN$33,882
- GVOKE HYPOPEN$17,940
- LYUMJEV$9,725
- Minimed 630G$5,625
- FreeStyle Libre Pro$3,413
- FREESTYLE LIBRE 3$2,100
- TRULICITY$1,793
- FreeStyle Libre$1,515
- FreeStyle Libre 2$788
- Minimed 670G System$300
- CeQur Simplicity$144
How this compares
$734,576 in reported general payments places this provider in the 95th percentile of 130 endocrinology, diabetes & metabolism providers in Tennessee.
See all endocrinology, diabetes & metabolism providers in Tennessee →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 475 | $598,114 |
| JardianceEmpagliflozin | 327 | $429,045 |
| OzempicSemaglutide | 231 | $309,250 |
| TrulicityDulaglutide | 101 | $157,982 |
| FarxigaDapagliflozin Propanediol | 52 | $68,929 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 79 | $58,614 |
| Tresiba Flextouch U-100Insulin Degludec | 62 | $58,116 |
| ForteoTeriparatide | 13 | $54,398 |
| Tresiba Flextouch U-200Insulin Degludec | 43 | $39,483 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 28 | $31,139 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 28 | $30,224 |
| Novolog FlexpenInsulin Aspart | 99 | $27,089 |
| Gvoke Hypopen 2-PackGlucagon | 37 | $25,687 |
| TradjentaLinagliptin | 18 | $24,002 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 118 | $21,056 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Forteo, Humalog | $452,935 | $813,378606 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr, Jentadueto | $135,869 | $476,644371 claims |
| Novo NordiskOzempic, Novolog | $111,355 | $315,545249 claims |
| AstraZenecaFarxiga | $47 | $68,92952 claims |
| MerckJanuvia, Janumet Xr | $122 | $26,77626 claims |
| AbbVieSynthroid | $169 | $5,86465 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 130 endocrinology, diabetes & metabolism providers in Tennessee.
Other endocrinology, diabetes & metabolism in Memphis
- Alan CohenMemphis$1.4M
- Samuel Dagogo-JackMemphis$407K
- Aidar GosmanovMemphis$138K
- Malini GuptaMemphis$91K
- Benjamin BrannickMemphis$84K
- Pedro VelasquezMemphis$21K
- Fariha SalmanMemphis$14K
- Maher GhawjiMemphis$13K
- Yunna JiangMemphis$12K
- Rabia RehmanMemphis$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.